At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHAT Phathom Pharmaceuticals
Market Closed 10-09 16:00:00 EDT
7.25
+0.12
+1.68%
盘后7.25
+0.000.00%
19:30 EDT
High7.30Low7.02Vol928.34K
Open7.13D1 Closing7.13Amplitude4.00%
Mkt Cap586.53MTradable Cap463.47MTotal Shares80.90M
T/O6.71MT/O Rate1.45%Tradable Shares63.93M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Phathom Pharmaceuticals Presents New Voquezna Analyses in GERD at ACG 2026 Meeting
Reuters  ·  10-08 20:02
Phathom Pharmaceuticals Presents New Voquezna Analyses in GERD at ACG 2026 Meeting
Phathom’s Vonoprazan Trial Targets Episodic Heartburn Upside for PHAT Investors
TIPRANKS  ·  10-08
Phathom’s Vonoprazan Trial Targets Episodic Heartburn Upside for PHAT Investors
Phathom Begins Phase 3 Trial of Voquezna As-Needed Dosing in Non-Erosive GERD Patients
Reuters  ·  09-29
Phathom Begins Phase 3 Trial of Voquezna As-Needed Dosing in Non-Erosive GERD Patients
Phathom Pharmaceuticals, - Topline Results from Phase 3 Study Expected in Q1 2028
THOMSON REUTERS  ·  09-29
Phathom Pharmaceuticals, - Topline Results from Phase 3 Study Expected in Q1 2028
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of Voquezna® (Vonoprazan) for As-Needed Treatment of Non-Erosive Gerd
THOMSON REUTERS  ·  09-29
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of Voquezna® (Vonoprazan) for As-Needed Treatment of Non-Erosive Gerd
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
GlobeNewswire  ·  09-29
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
H.C. Wainwright Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)
TIPRANKS  ·  09-22
H.C. Wainwright Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals Initiated at Market Perform by Leerink Partners
Dow Jones  ·  09-09
Phathom Pharmaceuticals Initiated at Market Perform by Leerink Partners
Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT
MT Newswires Live  ·  09-09
Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT
Phathom Pharmaceuticals initiated with a Market Perform at Leerink
TIPRANKS  ·  09-09
Phathom Pharmaceuticals initiated with a Market Perform at Leerink
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  09-01
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN)
TIPRANKS  ·  08-17
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN)
Phathom Pharmaceuticals’ Earnings Call Signals Profitable Growth
TIPRANKS  ·  08-16
Phathom Pharmaceuticals’ Earnings Call Signals Profitable Growth
Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough
Simply Wall St.  ·  08-01
Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough
Phathom Pharmaceuticals is Maintained at Buy by Needham
Dow Jones  ·  07-31
Phathom Pharmaceuticals is Maintained at Buy by Needham
Phathom Pharmaceuticals price target lowered to $22 from $28 at Needham
TIPRANKS  ·  07-31
Phathom Pharmaceuticals price target lowered to $22 from $28 at Needham
Phathom Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  07-31
Phathom Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Phathom Pharmaceuticals Down over 19%, on Track for Largest Percent Decrease Since May 2025
Dow Jones  ·  07-31
Phathom Pharmaceuticals Down over 19%, on Track for Largest Percent Decrease Since May 2025
Phathom Pharmaceuticals Q2 Revenue Beats on Voquezna Prescription Growth
Reuters  ·  07-30
Phathom Pharmaceuticals Q2 Revenue Beats on Voquezna Prescription Growth
Phathom Q2 GAAP Net Loss Narrows to $17.6 Million from Year-ago; Revenue Rises 88% to $74.3 Million
Reuters  ·  07-30
Phathom Q2 GAAP Net Loss Narrows to $17.6 Million from Year-ago; Revenue Rises 88% to $74.3 Million

Introduction

Company Name.
Phathom Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Issue price:
--